Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
Anticancer Res. 2023 May;43(5):2351-2357. doi: 10.21873/anticanres.16400.
BACKGROUND/AIM: Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting. To identify risk factors for nausea and vomiting, we investigated the occurrence of nausea and vomiting in mCRC patients treated with TAS-102 and BEV.
Study patients with mCRC received TAS-102 and BEV between March 2016 and December 2021. The status of nausea, vomiting, and antiemetic measures in each course were investigated, and factors involved in the occurrence of nausea and vomiting were analysed by logistic regression analysis.
Data from 57 patients were analysed. The incidence rates of nausea and vomiting during the overall period were 57.9% and 17.5%, respectively. Nausea and vomiting were frequent not only in the early courses but also after the sixth course. Multivariate logistic regression analysis showed that the experience of nausea and vomiting in previous treatment with other agents was significantly associated with nausea and vomiting with TAS-102 and BEV.
The experience of nausea and vomiting in previous treatment was associated with increased risk for nausea and vomiting in mCRC patients treated with TAS-102 and BEV.
背景/目的：三氟尿苷/替匹嘧啶（TAS-102）联合贝伐珠单抗（BEV）的化疗方案对转移性不可切除结直肠癌（mCRC）具有高度疗效，但该联合化疗方案常引起恶心和呕吐。为了明确恶心和呕吐的相关风险因素，我们对接受 TAS-102 和 BEV 治疗的 mCRC 患者的恶心和呕吐发生情况进行了研究。
2016 年 3 月至 2021 年 12 月，mCRC 患者接受 TAS-102 和 BEV 治疗。调查了每位患者在各疗程中恶心、呕吐的发生情况以及止吐措施的应用情况，并通过 logistic 回归分析对与恶心和呕吐发生相关的因素进行了分析。
共分析了 57 例患者的数据。总体期间恶心和呕吐的发生率分别为 57.9%和 17.5%。恶心和呕吐不仅在早期疗程中较为频繁，在第六个疗程后也很常见。多变量 logistic 回归分析显示，既往其他药物治疗中出现恶心和呕吐的经历与 TAS-102 和 BEV 治疗时的恶心和呕吐显著相关。
既往治疗中出现恶心和呕吐的经历与 mCRC 患者接受 TAS-102 和 BEV 治疗时恶心和呕吐风险增加相关。
